Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Developing a Genomics Model to Predict Failure of Isocitrate Dehydrogenase (IDH) Inhibitors for Treatment of Patients with IDH1- or IDH2-Mutated Acute Myeloid Leukemia

Tigran Ghazanchyan, MS, Dickran Kazandjian, MD, Donna Przepiorka, MD PhD, Kelly J. Norsworthy, MD, Emma Scott, PhD, Luis Santana-Quintero, PhD, Svetlana Petrovskaya, PhD, Yong Zhang, PhD, Amy Rosenberg, MD, Ashutosh Rao, PhD, Richard Pazdur, MD, Ann T. Farrell, MD, Julia A. Beaver, MD, Vahan Simonyan, PhD

Blood (2018) 132 (Supplement 1): 2815.

https://doi.org/10.1182/blood-2018-99-116870

Published: 2018

Journal Articles

Idelalisib for Treatment of Follicular Lymphoma and Chronic Lymphocytic Leukemia in Clinical Trials Versus the Real World: Treatment Duration and Survival Are Associated with Pretreatment Modified Charlson Score

Steven T Bird, PhD PharmD, Natasha Flowers, BA, Fang Tian, PhD MHS, MPH, Donna Przepiorka, MD PhD, Tae Hyun Jung, PhD, Rongrong Wang, MPH, Zebulin Kessler, BS, Corinne Woods, RPh, MPH, Bo Kim, BA, Barry W. Miller, MS, CNP, Michael Wernecke, BA, Stephen McKean, PhD, Clara Kim, PhD, Kate Gelperin, MD MPH, Jeffrey A Kelman, MD MMSc, David J Graham, MD MPH

Blood (2018) 132 (Supplement 1): 2889.

https://doi.org/10.1182/blood-2018-99-116498

Published: 2018

Journal Articles

Exploration of PRO-CTCAE Data Used for Exposure-Response Relationships in an Oncology Clinical Trial

Huiming Xia, PhD MS, Jeanne Zirkelbach Fourie, PhD, Brian Booth, PhD, Yaning Wang, PhD M.A., Mallorie H. Fiero, PhD, Donna Przepiorka, MD PhD, Paul Kluetz, MD

Blood (2017) 130 (Supplement 1): 5670.

https://doi.org/10.1182/blood.V130.Suppl_1.5670.5670

Published: 2017

Journal Articles

Oral Voriconazole for Empiric Antifungal Treatment in Uncomplicated Febrile Neutropenic Patients.

Kara Keasler, PharmD, Joyce Broyles, Pharm.D., Brian McClune, DO, Francis Buadi, MD, Donna Przepiorka, MD, PhD

Blood (2006) 108 (11): 5494.

https://doi.org/10.1182/blood.V108.11.5494.5494

Published: 2006

Journal Articles

Myelodysplasia after Autologous Stem Cell Transplantation for Multiple Myeloma.

Gregory Franz, MD, Brian McClune, DO, Francis Buadi, MD, William Walsh, MD, Frank White, MD, Donna Przepiorka, MD, PhD

Blood (2006) 108 (11): 5329.

https://doi.org/10.1182/blood.V108.11.5329.5329

Published: 2006

Journal Articles

The Addition of Rituximab to Standard High Dose BEAM Chemotherapy for Autologous Stem Cell Transplant in Patients with Lymphoma Does Have a Significant Effect on Engraftment.

Francis K. Buadi, MD, Brian McClune, MD, Yoriann S. Hull, Furhan Yunus, MD, Sohail Minhas, MD, Donna Przepiorka, MD, PhD

Blood (2005) 106 (11): 5325.

https://doi.org/10.1182/blood.V106.11.5325.5325

Published: 2005

Journal Articles

Natural History of Relapse after Autologous Stem Cell Transplantation for Multiple Myeloma.

Brian McClune, DO, Francis Buadi, MD, Furhan Yunus, MD, Sohail Minhas, MD, William Walsh, MD, Donna Przepiorka, MD, PhD

Blood (2005) 106 (11): 5511.

https://doi.org/10.1182/blood.V106.11.5511.5511

Published: 2005

Journal Articles

Intrathecal Liposomal Cytarabine (Depocyt) Is Safe and Effective for Prevention of Meningeal Disease in Patients with Acute Lymphoblastic Leukemia and High-Grade Lymphoma Treated with the HyperCVAD Regimen.

Brian McClune, DO, Francis Buadi, MD, Naveed Aslam, MD, Donna Przepiorka, MD, PhD

Blood (2005) 106 (11): 4594.

https://doi.org/10.1182/blood.V106.11.4594.4594

Published: 2005

Journal Articles

African Americans and Caucasians with Myeloma Have Similar Outcomes in the Current Era: A Tumor Registry Study.

Brian McClune, MD, Birendra Kumar, MD, Francis Buadi, MD, Robin Womeodu, MD, Kathy Wright, Reed Baskin, MD, Sohail Minhas, MD, Thomas W. Ratliff, MD, Kathleen Spiers, MD, Furhan Yunus, MD, Donna Przepiorka, MD, PhD

Blood (2004) 104 (11): 3134.

https://doi.org/10.1182/blood.V104.11.3134.3134

Published: 2004

Journal Articles

Race Has No Effect on Survival in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation.

Francis Buadi, MD, Brian McClune, MD, Yoriann Moore, Robin Womeodu, MD, Furhan Yunus, MD, William Walsh, MD, Sohail Minhas, MD, Donna Przepiorka, MD

Blood (2004) 104 (11): 5242.

https://doi.org/10.1182/blood.V104.11.5242.5242

Published: 2004

NARROW

Developing a Genomics Model to Predict Failure of Isocitrate Dehydrogenase (IDH) Inhibitors for Treatment of Patients with IDH1- or IDH2-Mutated Acute Myeloid Leukemia

Idelalisib for Treatment of Follicular Lymphoma and Chronic Lymphocytic Leukemia in Clinical Trials Versus the Real World: Treatment Duration and Survival Are Associated with Pretreatment Modified Charlson Score

Exploration of PRO-CTCAE Data Used for Exposure-Response Relationships in an Oncology Clinical Trial

Oral Voriconazole for Empiric Antifungal Treatment in Uncomplicated Febrile Neutropenic Patients.

Myelodysplasia after Autologous Stem Cell Transplantation for Multiple Myeloma.

The Addition of Rituximab to Standard High Dose BEAM Chemotherapy for Autologous Stem Cell Transplant in Patients with Lymphoma Does Have a Significant Effect on Engraftment.

Natural History of Relapse after Autologous Stem Cell Transplantation for Multiple Myeloma.

Intrathecal Liposomal Cytarabine (Depocyt) Is Safe and Effective for Prevention of Meningeal Disease in Patients with Acute Lymphoblastic Leukemia and High-Grade Lymphoma Treated with the HyperCVAD Regimen.

African Americans and Caucasians with Myeloma Have Similar Outcomes in the Current Era: A Tumor Registry Study.

Race Has No Effect on Survival in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only